|
| 36305522 | Early phase oncology clinical trials in Malaysia: current status and future perspectives. | Asia Pac J Clin Oncol | 2023 |
| 37597246 | Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer. | Oncologist | 2023 |
| 37704538 | Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer. | Clin Colorectal Cancer | 2023 |
| 37699332 | Peeling the I-Onion to Demystify Pseudoprogression. | Cancer Cell | 2023 |
| 37641393 | Precision cancer medicine: Concepts, current practice, and future developments. | J Intern Med | 2023 |
| 37566240 | Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial. | Clin Cancer Res | 2023 |
| 37419999 | A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events. | Br J Cancer | 2023 |
| 37182343 | Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients. | Eur J Cancer | 2023 |
| 37040046 | Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors. | Invest New Drugs | 2023 |
| 37329221 | Clinical and metabolomic characterization of Brivanib-Induced hypertension in metastatic colorectal cancer. | Cancer Med | 2023 |
| 37027812 | Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials. | JCO Precis Oncol | 2023 |
| 36746689 | Antibody-drug conjugates: in search of partners of choice. | Trends Cancer | 2023 |
| 36806911 | Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. | Clin Cancer Res | 2023 |
| 36535566 | Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. | Ann Oncol | 2023 |
| 36826995 | Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma. | Clin Cancer Res | 2023 |
| 36670100 | Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy. | Cell Death Dis | 2023 |
| 36454221 | Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance. | Br J Clin Pharmacol | 2023 |
| 36863483 | First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial). | Ann Oncol | 2023 |
| 34598945 | First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2022 |
| 35705312 | Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab. | J Immunother Cancer | 2022 |
| 35379580 | All is not lost: learning from 9p21 loss in cancer. | Trends Immunol | 2022 |
| 35699599 | First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2022 |
| 35635640 | A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study. | Target Oncol | 2022 |
| 35717535 | Challenges and opportunities for physician-scientists in advancing cancer research. | Trends Cancer | 2022 |
| 35419588 | Correction: First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2022 |
| 36636086 | Outcomes of patients with esophageal cancer after allogeneic hematopoietic stem cell transplantation. | J Gastrointest Oncol | 2022 |
| 36636049 | A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. | J Gastrointest Oncol | 2022 |
| 36860696 | Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation. | Cancer Res Commun | 2022 |
| 36106403 | Correction: First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2022 |
| 36325690 | The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. | Mol Cancer Ther | 2022 |
| 36325685 | The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. | Mol Cancer Res | 2022 |
| 35921760 | Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors. | ESMO Open | 2022 |
| 36321301 | The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. | Cancer Epidemiol Biomarkers Prev | 2022 |
| 36321298 | The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. | Cancer Immunol Res | 2022 |
| 36321294 | The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. | Blood Cancer Discov | 2022 |
| 36321264 | The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. | Cancer Res | 2022 |
| 36084619 | A risk stratification model for toxicities in phase 1 immunotherapy trials. | Eur J Cancer | 2022 |
| 36008705 | Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE. | Br J Cancer | 2022 |
| 36317374 | The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. | Clin Cancer Res | 2022 |
| 36317369 | The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. | Cancer Prev Res (Phila) | 2022 |
| 35130943 | Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. | J Exp Clin Cancer Res | 2022 |
| 35285488 | Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents. | Oncologist | 2022 |
| 35247924 | A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2022 |
| 35274718 | Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials. | Oncologist | 2022 |
| 35028011 | Early detection of treatment futility in patients with metastatic colorectal cancer. | Oncotarget | 2022 |
| 35080978 | Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges. | Sci Adv | 2022 |
| 32880604 | The Day After COVID-19-Time to Rethink Oncology Clinical Research. | JAMA Oncol | 2021 |
| 36778585 | CanDIG: Federated network across Canada for multi-omic and health data discovery and analysis. | Cell Genom | 2021 |
| 33686237 | Beyond immune checkpoint blockade: emerging immunological strategies. | Nat Rev Drug Discov | 2021 |
| 33571468 | SARS-CoV-2 vaccination and phase 1 cancer clinical trials. | Lancet Oncol | 2021 |